Anavex launches study of blarcamesine in Rett syndrome

|About: Anavex Life Sciences C... (AVXL)|By:, SA News Editor

Anavex Life Sciences (AVXL +3.5%) initiates an international clinical trial, EXCELLENCE, evaluating ANAVEX 2-73 (blarcamesine) in ~69 pediatric patients with rare inherited neurological disorder called Rett syndrome. The first site, in Australia, will be launched in the next several quarters.

Two Phase 2 studies, AVATAR and ANAVEX-73-RS-001, evaluating ANAVEX 2-73 in Rett patients are currently enrolling participants.

Subscribe for full text news in your inbox